News ArticleResearchers have identified a genetic biomarker that can predict a patient's likelihood of experiencing taxane-induced peripheral neuropathy.Older people and blacks, the same study found, are at elevated risk of developing neuropathy, which affects up to a third of people receiving chemotherapy with taxane drugs such as paclitaxel.The marker in the RWDD3 gene, if developed into a blood test, would allow clinicians to identify patients vulnerable to peripheral neuropathy, which is characterized...